Erectile Dysfunction
Conditions
Keywords
erectile dysfunction, chronic renal dysfunction, tadalafil
Brief summary
The purpose of this study is to check the safety and efficacy of a pde5 inhibitor, tadalafil, is a special group of patients: Renal chronic patients in hemodialysis treatment.
Detailed description
In our country, the number of patients in hemodialysis for the treatment of renal chronic dysfunction is very huge. As we know this group has a greater prevalence of sexual dysfunction than the general population, and among these dysfunctions erectile disfunction(ED) occupies maybe the most important position. With the advent of the increase aging of the nation´s population and the small number of organ donations, the number of men suffering from ED in hemodialysis surely will be very significant causing a very important problem for our health system. Up to now there´s little indexed publications supporting the use of tadalafil in this special group of men. Another PDE 5 inhibitor, sildenafil, was used in this patients with success and safety but obviously we need other options with the same efficacy. We intend this study to give us more background to treat ED in this already unfortunate ones.
Interventions
DRUGtadalafil
Sponsors
University of Pernambuco
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Men between 18 and 70 years old * Diagnosticated ED for 6 months at least * Accept the protocol * Sign the informed consent * Renal chronic patients in hemodyalisis
Exclusion criteria
* History of another PDE5 inhibittor use. * C.C.I. grade III (NYHA)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IIEF 5 | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse effects reported | — |
Countries
Brazil
Contacts
Primary Contactbruno sp carvalho, md
Outcome results
None listed